Seeking Alpha

Novartis may jettison some of its small businesses

  • CEO Joe Jimenez' review of the viability of Novartis' (NVS) small divisions will probably mean that at least one will eventually be sold.
  • Three units: animal health, vaccines and OTC medicines won't globally scale so it the best solution for shareholders may be to get rid of them.
  • He cites the unattractive reimbursement environment as the main challenge for the businesses.
Comments (1)
  • SSnape
    , contributor
    Comments (472) | Send Message
    I would be really sorry to see NVS exit the animal health field.


    Long: NVS.
    20 Mar 2014, 02:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs